Founded in 2006, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē ® System is an innovative implantable neurostimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea. Sorin Group invested in on-going clinical testing of the remedē System in the U.S. Commercial launch of the product by Sorin in selected European countries started in 2015.